Lactomason
http://lactomason.tradekorea.com
AmBio, venture company foundation based on marine biotech, has its main business in Probiotics and Micro-algae. AmBio has their factory and R&D center in Jinju, and has their sales department is Seoul. Ambio have succeeded in developing the Membrane Cell Bioreactor cultivation technology which can cultivate 1 trillion live cells of Lactic acid bacteria per gram. It is the world premiere. Ambio have achieved New Excellent Technology(NET) and Health Technology(HT) certificate from the Korean government by developing this technology. Ambio is currently supplying their bulk products to the domestic and oversea market actively. Ambio is also spreading their business to the finished products. Ambio will do their best to lead the Korean marine biotechnology and aquaculture industry. Beyond their main business, Ambio is taking partnership with government research programs in aquaculture and marine biotechnology. Ambio will dedicate itself to found a human intra-sturcture in aquaculture and marine biotechnology.
Company Profile
Lactomason
- Business Type Manufacturer
- Year Established 2007
- Location South Korea
- Main Markets China,Indonesia,Thailand,Taiwan,Viet Nam
- Total Employees 51-100 People
- Homepage www.lactomason.com
